GLP-1, the Gut-brain, and Brain-periphery Axes

Overview

Journal Rev Diabet Stud

Specialty Endocrinology

Date 2012 Jan 21

PMID 22262078

Citations 41

Authors

Cendrine Cabou

Remy Burcelin

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide 1 (GLP-1) is a gut hormone which directly binds to the GLP-1 receptor located at the surface of the pancreatic β-cells to enhance glucose-induced insulin secretion. In addition to its pancreatic effects, GLP-1 can induce metabolic actions by interacting with its receptors expressed on nerve cells in the gut and the brain. GLP-1 can also be considered as a neuropeptide synthesized by neuronal cells in the brain stem that release the peptide directly into the hypothalamus. In this environment, GLP-1 is assumed to control numerous metabolic and cardiovascular functions such as insulin secretion, glucose production and utilization, and arterial blood flow. However, the exact roles of these two locations in the regulation of glucose homeostasis are not well understood. In this review, we highlight the latest experimental data supporting the role of the gut-brain and brain-periphery axes in the control of glucose homeostasis. We also focus our attention on the relevance of β-cell and brain cell targeting by gut GLP-1 for the regulation of glucose homeostasis. In addition to its action on β-cells, we find that understanding the physiological role of GLP-1 will help to develop GLP-1-based therapies to control glycemia in type 2 diabetes by triggering the gut-brain axis or the brain directly. This pleiotropic action of GLP-1 is an important concept that may help to explain the observation that, during their treatment, type 2 diabetic patients can be identified as 'responders' and 'non-responders'.

Citing Articles

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.

Radkhah H, Rahimipour Anaraki S, Roudsari P, Bahri R, Zooravar D, Asgarian S Eat Weight Disord. 2025; 30(1):10.

PMID: 39891848 PMC: 11787217. DOI: 10.1007/s40519-025-01720-9.

Dysregulation of Metabolic Peptides in the Gut-Brain Axis Promotes Hyperinsulinemia, Obesity, and Neurodegeneration.

Green C, Zaman V, Blumenstock K, Banik N, Haque A Biomedicines. 2025; 13(1).

PMID: 39857716 PMC: 11763097. DOI: 10.3390/biomedicines13010132.

The Gut Microbiome's Influence on Incretins and Impact on Blood Glucose Control.

Dulai A, Min M, Sivamani R Biomedicines. 2025; 12(12.

PMID: 39767626 PMC: 11727616. DOI: 10.3390/biomedicines12122719.

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury.

Harej Hrkac A, Pilipovic K, Belancic A, Juretic L, Vitezic D, Mrsic-Pelcic J Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458954 PMC: 11510130. DOI: 10.3390/ph17101313.

Food Addiction.

Krupa H, Gearhardt A, Lewandowski A, Avena N Brain Sci. 2024; 14(10).

PMID: 39451967 PMC: 11506718. DOI: 10.3390/brainsci14100952.

References

Deacon C . Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2005; 36(11-12):761-5. DOI: 10.1055/s-2004-826160. View

Wei Y, Mojsov S . Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995; 358(3):219-24. DOI: 10.1016/0014-5793(94)01430-9. View

Mentis N, Vardarli I, Kothe L, Holst J, Deacon C, Theodorakis M . GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011; 60(4):1270-6. PMC: 3064100. DOI: 10.2337/db10-1332. View

Yamamoto H, Kishi T, Lee C, Choi B, Fang H, Hollenberg A . Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci. 2003; 23(7):2939-46. PMC: 6742071. View

Holst J, Deacon C . Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005; 48(4):612-5. DOI: 10.1007/s00125-005-1705-7. View

Burcelin R, Dolci W, Thorens B . Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization. Diabetes. 2000; 49(10):1635-42. DOI: 10.2337/diabetes.49.10.1635. View

Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan D, Varela L, Haynes W . Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009; 29(18):5916-25. PMC: 6665241. DOI: 10.1523/JNEUROSCI.5977-08.2009. View

Suzuki Y, Zhang H, Saito N, Kojima I, Urano T, Mogami H . Glucagon-like peptide 1 activates protein kinase C through Ca2+-dependent activation of phospholipase C in insulin-secreting cells. J Biol Chem. 2006; 281(39):28499-507. DOI: 10.1074/jbc.M604291200. View

Polak J, Bloom S, Kuzio M, Brown J, Pearse A . Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum. Gut. 1973; 14(4):284-8. PMC: 1412599. DOI: 10.1136/gut.14.4.284. View

10.

Baron A, Steinberg H, Chaker H, LEAMING R, Johnson A, Brechtel G . Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 1995; 96(2):786-92. PMC: 185264. DOI: 10.1172/JCI118124. View

11.

Thorens B . Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A. 1992; 89(18):8641-5. PMC: 49976. DOI: 10.1073/pnas.89.18.8641. View

12.

Steinberg H, Brechtel G, Johnson A, Fineberg N, Baron A . Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 1994; 94(3):1172-9. PMC: 295191. DOI: 10.1172/JCI117433. View

13.

Ruttimann E, Arnold M, Hillebrand J, Geary N, Langhans W . Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology. 2008; 150(3):1174-81. PMC: 2654737. DOI: 10.1210/en.2008-1221. View

14.

Steinberg H, Chaker H, LEAMING R, Johnson A, Brechtel G, Baron A . Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996; 97(11):2601-10. PMC: 507347. DOI: 10.1172/JCI118709. View

15.

Shimizu N, Oomura Y, Novin D, Grijalva C, Cooper P . Functional correlations between lateral hypothalamic glucose-sensitive neurons and hepatic portal glucose-sensitive units in rat. Brain Res. 1983; 265(1):49-54. DOI: 10.1016/0006-8993(83)91332-x. View

16.

Brown J, Dryburgh J, Ross S, Dupre J . Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res. 1975; 31:487-532. DOI: 10.1016/b978-0-12-571131-9.50017-7. View

17.

Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van der Veken P, Augustyns K . Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem. 2011; 392(3):189-98. DOI: 10.1515/BC.2011.002. View

18.

Vrang N, Just Larsen P, Jensen P, Lykkegaard K, Artmann A, Larsen L . Upregulation of the brainstem preproglucagon system in the obese Zucker rat. Brain Res. 2007; 1187:116-24. DOI: 10.1016/j.brainres.2007.10.026. View

19.

Hoyt E, Lund P, Winesett D, Fuller C, Ghatei M, Bloom S . Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Diabetes. 1996; 45(4):434-9. DOI: 10.2337/diab.45.4.434. View

20.

Scrocchi L, Brown T, MacLusky N, Brubaker P, AUERBACH A, Joyner A . Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996; 2(11):1254-8. DOI: 10.1038/nm1196-1254. View